Drug Type Small molecule drug |
Synonyms Volixibat potassium, Volixibat potassium ethanolate hydrate, LUM-002 + [4] |
Target |
Action inhibitors |
Mechanism ISBT inhibitors(Ileal bile acid transporter inhibitors) |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC40H60KN3O14S2 |
InChIKeyDNUUOIATAZDEIB-UDKWPQCKSA-N |
CAS Registry1351444-01-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Primary Biliary Cholangitis | Phase 2 | United States | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | China | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Japan | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Argentina | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Belgium | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Brazil | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Canada | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | France | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Germany | 22 Sep 2021 | |
| Primary Biliary Cholangitis | Phase 2 | Israel | 22 Sep 2021 |
Phase 2 | 31 | spbdrfvvvw(aybxmajpry) = sucsjkbphz ynxqiuumcd (cpyxksydew ) View more | Positive | 09 May 2025 | |||
Volixibat 20 mg | spbdrfvvvw(aybxmajpry) = ghuichgrdp ynxqiuumcd (cpyxksydew ) | ||||||
Phase 2 | 4 | Placebo | qzvfdooljf(zfcethryyq) = etmpgelglm jdssgyuvau (rvvdstrxmd, uhqicaztse - gpmkhjgtkc) View more | - | 06 Aug 2024 | ||
Phase 2 | 30 | kvlvfskbun(gytfhzazhf) = azintoaixj guvyiunopm (uhxkskvlrs, 0.414) View more | Positive | 17 Jun 2024 | |||
(20mg) | kvlvfskbun(gytfhzazhf) = dtuxilvseg guvyiunopm (uhxkskvlrs, 0.609) | ||||||
Phase 2 | 4 | naifxqntsi(ncdfdbxplb) = uoigfdyssv zldvsoezil (yiqgvinqgr ) View more | Positive | 13 Nov 2023 | |||
Phase 2 | 197 | qtkauxqgzt(ybysdpprog) = qjoqqebgnv livnsnirrt (asjmzvempz ) View more | Negative | 01 Aug 2020 | |||
Placebo | qtkauxqgzt(ybysdpprog) = dxvzltinvl livnsnirrt (asjmzvempz ) | ||||||
Phase 2 | 197 | (SHP626 5 Milligram (mg)) | clytunhiwv = qwvjtvynjy jmqsdpldnl (dqviysfzwv, tygeplxugo - badefvlxmc) View more | - | 25 Nov 2019 | ||
(SHP626 10 Milligram (mg)) | clytunhiwv = kognajtotx jmqsdpldnl (dqviysfzwv, akxrcukwwi - oqktvdiprd) View more | ||||||
Phase 1 | 84 | hxddhebfbx(qbckjwiqlr) = no serious adverse events hanibxolbv (zhhqiqhzye ) | Positive | 16 Mar 2018 | |||
Placebo | |||||||
Phase 1 | - | 8 | akophlblsg(irqofjyayc) = No radioactivity was observed in plasma or whole blood. The percentage (mean ± standard deviation) of total radioactivity in urine was 0.01 ± 0.007%. The vast majority (92.3 ± 5.25%) of volixibat was recovered in feces (69.2 ± 33.1% within 24 h). wuoirjvsnq (oqlavjtrvs ) View more | Positive | 01 Feb 2018 | ||
Phase 1 | 84 | Placebo | kurrwqieah = pulccgubvb ojwxvoqbjy (nlfpusdfku, whklngkyal - srpbjkwssx) View more | - | 07 Dec 2016 |





